$913,000 Cynata entitlement offer implies 37.5% share issuance

$913,000 Raise Targets Strategic Survival

Cynata Therapeutics Limited (ASX:CYP) is asking shareholders for $913,000 to keep its strategic options open, rather than to restart a major clinical program. The three-for-eight renounceable entitlement offer is fully underwritten by Caravel Securities at $0.01 a share, a 9.1% discount to Cynata’s 7 October closing price and five-day volume-weighted average price.

The capital raising comes after the company’s Phase 2 CYP-001 acute graft versus host disease trial and Phase 3 CYP-004 osteoarthritis trial failed to demonstrate the efficacy required to support further development in their current form. That earlier trial failure update also detailed a $553,774 net liability position and a material uncertainty over going concern.

Cash Provides Runway, Not a New Clinical Budget

Cynata says the funds will cover director, consultant and professional adviser costs tied to its strategic objectives, offer expenses and general working capital. The prospectus allocates $300,000 to director and consultant costs, $250,000 to legal, patent attorney and other professional fees, $100,000 to insurance, $149,166 to offer costs and $650,129 to general working capital.

The company reported $536,295 in cash at 8 October after recent cash movements. On the prospectus’s fully subscribed assumptions, the offer would lift pro forma cash to about $1.30 million after costs, while total assets would rise to $1.75 million and net assets to $1.46 million. Those figures are illustrative rather than a forecast: Cynata says it has not included financial forecasts because of the nature of its business and operations.

Cymerus Strategy Moves From Trials to Transactions

The board says it is evaluating future development pathways for the Cymerus platform, which is designed to manufacture mesenchymal stromal cells at commercial scale from a single consistent cell source. That review includes seeking ways to realise value through licensing, partnering or other strategic transactions, as well as obtaining rights to new assets.

The prospectus is blunt about the limits of the new capital. Cynata says it does not generate operating revenue to fund material development activity, that the offer may not be enough to fulfil its strategic objectives, and that further funding is likely to be required, particularly if it secures new assets. It also says the company may be unable to continue as a going concern if the offer does not complete.

Free Options Increase Future Dilution

Participants receive one unquoted option for every three new shares issued. Each option carries a $0.02 exercise price and expires two years and six months after issue. If the offer is fully subscribed, Cynata expects to issue 91.3 million new shares and 30.4 million entitlement options, taking shares on issue from 243.5 million to 334.7 million.

Caravel will also receive 18 million options on the same terms as payment for underwriting services, alongside cash fees of 3% of gross proceeds and 6% of any shortfall amount. If all options issued under the offer and to the underwriter were exercised, the company says its share count could reach 383.2 million, representing 12.64% dilution after exercise. In an extreme scenario where shareholders and sub-underwriters provided no support, the underwriter could acquire about 27.3% of Cynata, although Caravel says it expects sub-underwriting or other firm commitments to limit any material control effect.